Summit makes case for changes to antibiotic R&D after sharing data from failed phase 3 trial

Ten months after revealing a phase 3 flop, Summit Therapeutics has shared data from an antibiotic trial and framed it as evidence of a potential need to change how anti-infectives are developed and assessed.